tetano
Editor, Senior Moderator
Cardiovasc Res
. 2020 Jul 23;cvaa209.
doi: 10.1093/cvr/cvaa209. Online ahead of print.
The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study
Kenneth Mangion[SUP] 1 2 [/SUP], Andrew Morrow[SUP] 1 2 [/SUP], Catherine Bagot[SUP] 3 [/SUP], Hannah Bayes[SUP] 4 [/SUP], Kevin G Blyth[SUP] 5 6 [/SUP], Colin Church[SUP] 5 [/SUP], David Corcoran[SUP] 1 2 [/SUP], Christian Delles[SUP] 1 [/SUP], Lynsey Gillespie[SUP] 7 [/SUP], Douglas Grieve[SUP] 8 [/SUP], Antonia Ho[SUP] 9 [/SUP], Sharon Kean[SUP] 10 [/SUP], Ninian N Lang[SUP] 1 2 [/SUP], Vera Lennie[SUP] 11 [/SUP], David Lowe[SUP] 12 [/SUP], Peter Kellman[SUP] 13 [/SUP], Peter W Macfarlane[SUP] 14 [/SUP], Alex McConnachie[SUP] 9 [/SUP], Giles Roditi[SUP] 15 [/SUP], Robert Sykes[SUP] 1 16 [/SUP], Rhian M Touyz[SUP] 1 2 [/SUP], Naveed Sattar[SUP] 1 [/SUP], Ryan Wereski[SUP] 2 11 17 [/SUP], Sylvia Wright[SUP] 18 [/SUP], Colin Berry[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: COVID-19 is typically a primary respiratory illness with multisystem involvement. The prevalence and clinical significance of cardiovascular and multisystem involvement in COVID-19 remain unclear.
Methods: This is a prospective, observational, multicentre, longitudinal, cohort study with minimal selection criteria and a near-consecutive approach to screening. Patients who have received hospital care for COVID-19 will be enrolled within 28 days of discharge. Myocardial injury will be diagnosed according to the peak troponin I in relation to the upper reference limit (URL, 99th centile) (Abbott Architect troponin I assay; sex-specific URL, male: >34 ng/L; female: >16 ng/L). Multisystem, multimodality imaging will be undertaken during the convalescent phase at 28 days post-discharge (Visit 2). Imaging of the heart, lung, and kidneys will include multiparametric, stress perfusion, cardiovascular magnetic resonance imaging, and computed tomography coronary angiography. Health and well-being will be assessed in the longer term. The primary outcome is the proportion of patients with a diagnosis of myocardial inflammation.
Conclusion: CISCO-19 will provide detailed insights into cardiovascular and multisystem involvement of COVID-19. Our study will inform the rationale and design of novel therapeutic and management strategies for affected patients.
. 2020 Jul 23;cvaa209.
doi: 10.1093/cvr/cvaa209. Online ahead of print.
The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study
Kenneth Mangion[SUP] 1 2 [/SUP], Andrew Morrow[SUP] 1 2 [/SUP], Catherine Bagot[SUP] 3 [/SUP], Hannah Bayes[SUP] 4 [/SUP], Kevin G Blyth[SUP] 5 6 [/SUP], Colin Church[SUP] 5 [/SUP], David Corcoran[SUP] 1 2 [/SUP], Christian Delles[SUP] 1 [/SUP], Lynsey Gillespie[SUP] 7 [/SUP], Douglas Grieve[SUP] 8 [/SUP], Antonia Ho[SUP] 9 [/SUP], Sharon Kean[SUP] 10 [/SUP], Ninian N Lang[SUP] 1 2 [/SUP], Vera Lennie[SUP] 11 [/SUP], David Lowe[SUP] 12 [/SUP], Peter Kellman[SUP] 13 [/SUP], Peter W Macfarlane[SUP] 14 [/SUP], Alex McConnachie[SUP] 9 [/SUP], Giles Roditi[SUP] 15 [/SUP], Robert Sykes[SUP] 1 16 [/SUP], Rhian M Touyz[SUP] 1 2 [/SUP], Naveed Sattar[SUP] 1 [/SUP], Ryan Wereski[SUP] 2 11 17 [/SUP], Sylvia Wright[SUP] 18 [/SUP], Colin Berry[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32702087
- DOI: 10.1093/cvr/cvaa209
Abstract
Background: COVID-19 is typically a primary respiratory illness with multisystem involvement. The prevalence and clinical significance of cardiovascular and multisystem involvement in COVID-19 remain unclear.
Methods: This is a prospective, observational, multicentre, longitudinal, cohort study with minimal selection criteria and a near-consecutive approach to screening. Patients who have received hospital care for COVID-19 will be enrolled within 28 days of discharge. Myocardial injury will be diagnosed according to the peak troponin I in relation to the upper reference limit (URL, 99th centile) (Abbott Architect troponin I assay; sex-specific URL, male: >34 ng/L; female: >16 ng/L). Multisystem, multimodality imaging will be undertaken during the convalescent phase at 28 days post-discharge (Visit 2). Imaging of the heart, lung, and kidneys will include multiparametric, stress perfusion, cardiovascular magnetic resonance imaging, and computed tomography coronary angiography. Health and well-being will be assessed in the longer term. The primary outcome is the proportion of patients with a diagnosis of myocardial inflammation.
Conclusion: CISCO-19 will provide detailed insights into cardiovascular and multisystem involvement of COVID-19. Our study will inform the rationale and design of novel therapeutic and management strategies for affected patients.